Puma Biotechnology | PBYI - Trade Debtors


Puma Biotechnology reported $28.1M in Trade Debtors for its fiscal quarter ending in June of 2024.





Trade Debtors Change Date
Agios Pharmaceuticals USD 5.03M 43K Sep/2025
Alnylam Pharmaceuticals USD 964.77M 397.66M Sep/2025
Amgen USD 9.57B 1.08B Dec/2025
Biogen USD 1.85B 234M Sep/2025
BioMarin Pharmaceutical USD 790.27M 65.59M Sep/2025
Daiichi Sankyo JPY 695.95B 79.1B Dec/2025
Esperion Therapeutics USD 60.36M 5.75M Jun/2024
Exelixis USD 286.92M 24.38M Dec/2025
Gilead Sciences USD 4.91B 182M Dec/2025
Glaxosmithkline GBP 11.16B 3.46B Sep/2025
Incyte USD 1.02B 128.52M Dec/2025
MacroGenics USD 69.23M 56.7M Sep/2025
Moderna USD 1.05B 589M Sep/2025
Novartis USD 8.98B 192M Sep/2025
Pfizer USD 18.12B 2.02B Sep/2025
PTC Therapeutics USD 203.07M 6.94M Sep/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Roche Holding CHF 11.9B 460M Dec/2025
Sangamo BioSciences USD 581K 110K Jun/2024
Sarepta Therapeutics USD 395.74M 213.86M Sep/2025
Takeda JPY 757.92B 55.68B Dec/2025
TG Therapeutics USD 265.38M 33.86M Sep/2025
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024
Vertex Pharmaceuticals USD 1.95B 52.9M Sep/2025